DEXCOM INC

Dexcom insider sales reveal a steady, pre‑planned divestment trend—yet the company’s growth in continuous glucose monitoring keeps upside potential alive.

Dexcom CFO’s routine 3,638‑share sale amid board expansion shows disciplined insider trading and confidence in the company’s growth.

Dexcom’s latest RSU grant to senior execs shows modest dilution, strong market confidence, and a clear strategy to align incentives with long‑term shareholder value.